Ocular Therapeutix Inc (NASDAQ:OCUL) Major Shareholder Purchases $189,367.00 in Stock

Ocular Therapeutix Inc (NASDAQ:OCUL) major shareholder Summer Road Llc purchased 40,900 shares of the company’s stock in a transaction on Thursday, March 19th. The shares were purchased at an average price of $4.63 per share, for a total transaction of $189,367.00. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Summer Road Llc also recently made the following trade(s):

  • On Tuesday, March 24th, Summer Road Llc bought 109,100 shares of Ocular Therapeutix stock. The stock was bought at an average price of $4.92 per share, for a total transaction of $536,772.00.
  • On Friday, March 13th, Summer Road Llc purchased 210,800 shares of Ocular Therapeutix stock. The stock was acquired at an average cost of $4.63 per share, with a total value of $976,004.00.
  • On Tuesday, March 17th, Summer Road Llc purchased 955,062 shares of Ocular Therapeutix stock. The stock was acquired at an average cost of $5.00 per share, with a total value of $4,775,310.00.

Shares of OCUL opened at $5.02 on Thursday. The stock has a fifty day moving average of $5.23 and a two-hundred day moving average of $4.18. The company has a debt-to-equity ratio of 5.07, a quick ratio of 4.92 and a current ratio of 5.00. The company has a market capitalization of $258.69 million, a PE ratio of -2.51 and a beta of 2.03. Ocular Therapeutix Inc has a fifty-two week low of $2.35 and a fifty-two week high of $8.12.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings data on Thursday, March 12th. The biopharmaceutical company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.08). Ocular Therapeutix had a negative return on equity of 801.90% and a negative net margin of 2,043.34%. The firm had revenue of $2.26 million for the quarter, compared to analyst estimates of $2.30 million. As a group, equities research analysts forecast that Ocular Therapeutix Inc will post -1.24 earnings per share for the current fiscal year.

Institutional investors have recently modified their holdings of the company. Creative Planning raised its stake in Ocular Therapeutix by 14.1% during the fourth quarter. Creative Planning now owns 18,713 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 2,313 shares during the period. Citigroup Inc. boosted its holdings in Ocular Therapeutix by 62.5% during the fourth quarter. Citigroup Inc. now owns 11,376 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 4,375 shares in the last quarter. Rhumbline Advisers boosted its holdings in Ocular Therapeutix by 9.6% during the fourth quarter. Rhumbline Advisers now owns 55,710 shares of the biopharmaceutical company’s stock worth $220,000 after buying an additional 4,864 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in Ocular Therapeutix by 5.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 114,755 shares of the biopharmaceutical company’s stock worth $454,000 after purchasing an additional 5,720 shares during the period. Finally, California State Teachers Retirement System boosted its stake in Ocular Therapeutix by 11.5% in the 3rd quarter. California State Teachers Retirement System now owns 64,606 shares of the biopharmaceutical company’s stock worth $196,000 after purchasing an additional 6,667 shares during the period. Institutional investors and hedge funds own 47.95% of the company’s stock.

OCUL has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and set a $8.00 target price on shares of Ocular Therapeutix in a report on Wednesday, March 4th. Jefferies Financial Group initiated coverage on Ocular Therapeutix in a research report on Tuesday, March 17th. They set a “buy” rating and a $8.00 price target for the company. ValuEngine upgraded Ocular Therapeutix from a “sell” rating to a “hold” rating in a research report on Wednesday, March 18th. Raymond James upgraded Ocular Therapeutix from an “outperform” rating to a “strong-buy” rating in a report on Tuesday, March 3rd. Finally, Zacks Investment Research upgraded Ocular Therapeutix from a “sell” rating to a “hold” rating in a report on Friday, March 13th. Three analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Ocular Therapeutix presently has an average rating of “Buy” and a consensus price target of $7.00.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery.

Read More: How can investors find ex-dividend dates?

Insider Buying and Selling by Quarter for Ocular Therapeutix (NASDAQ:OCUL)

Receive News & Ratings for Ocular Therapeutix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix and related companies with MarketBeat.com's FREE daily email newsletter.